财务表现 - Amylyx Pharmaceuticals, Inc. (AMLX)第四季度每股收益为0.07美元，低于Zacks Consensus Estimate的0.20美元[1] - Amylyx Pharmaceuticals, Inc.第四季度营收为1.0845亿美元，超过Zacks Consensus Estimate 1.93%[3] - Amylyx Pharmaceuticals, Inc.股价自年初以来上涨约4%，略低于标普500指数的涨幅[6]

Exhibit 99.1 Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results • Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter • Delivered $49.3 million in net income for the full year 2023, including $4.7 million in the fourth quarter, and ended the year with cash, cash equivalents and short-term investments of $371.4 million • Management to host conference call and webcast today at 8:00 a.m. Eastern Time CAMBRIDGE, Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41199 Amylyx Pharmaceuticals, Inc. (Exact name of Registrant as specified ...

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Law Group announces that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023. What Should Amylyx Pharmaceuticals Investors Do? If you invested in Amylyx Pharmaceuticals, visit our website by clicking here, or call us toll-free at (888) 410-2925 to discuss how you may be able to recover your losses. Our investi ...

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life. Thanks to companies in this sector, there are innovative and completely effective solutions for very complicated diseases. If you want to participate and contribute to companies in charge of improving human health, here are three biotech stocks to buy. Let’s take a quick look at these compan ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced it has completed enrollment of its Phase 2 HELIOS trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS), a rare genetic disease that typically results in neurodegeneration and premature death, which has no known cure. The trial has enrolled 12 adult participants living with WS, and preliminary results are anticipated in the sec ...

Key PointsAmylyx may get its flagship treatment for ALS approved by the European Medicines Agency (EMA), opening another avenue for revenue growth.  Puma Biotechnology will begin a mid-stage trial for its lead cancer drug.  Cassava Sciences forecasts top-line results for a Phase 3 study on its Alzheimer's disease drug to be available by the end of the calendar year.  5 stocks we like better than Amylyx PharmaceuticalsThere's a reason that many biotech investors prefer to stick with large-cap stocks. Investi ...

医药 - 药品股票公司比较 - Amylyx Pharmaceuticals, Inc. (AMLX) 和 Neurocrine Biosciences (NBIX) 是备受投资者关注的医药 - 药品股票公司[1] - AMLX 目前拥有 Zacks Rank 2 (买入)，而 NBIX 则为 Zacks Rank 3 (持有)[3] - AMLX 的前瞻市盈率为 10.06，而 NBIX 的前瞻市盈率为 29.42，PEG 比率分别为 0.15 和 0.75[6] 估值比较 - AMLX 的 P/B 比率为 2.52，而 NBIX 的 P/B 比率为 6.97[7] - 根据估值指标和其他数据，AMLX 的价值评级为 B，而 NBIX 的价值评级为 C[7] - AMLX 的估值指标和盈利预期修订活动均优于 NBIX，价值投资者可能会认为 AMLX 是当前更优选项[8]

Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life. In turn, the firms that can produce therapeutics that address human disease will always command high prices. That’s why we curated this list of the top-rated biotech stocks. Novel treatments with greater efficacy create incredible returns for firms and investors. Of course, Wall Street and the analysts who work at its firms pay close attention to this sector at all times. Those firm ...

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance. A bold claim but I believe there’s much validity to it.First and foremost, advanced medicine stocks help improve the human condition. Nobody in their last moments wished they had spent more time in the office. Instead, they regret that they didn’t spend en ...